Autres langues ORIC Pharmaceuticals, Inc. Börse Stuttgart

Actions

4TZ

US68622P1093

Recherche biotechnologique et médicale

Marché Fermé - Börse Stuttgart 21:56:17 13/10/2026			Varia. 5j.	Varia. 1 janv.
10,07 ^EUR	-4,50%		-4,83%	+52,83%

05/10	ORIC Pharmaceuticals, Inc. et Cancer Research UK annoncent un accord visant à faire entrer en développement clinique une thérapie ciblant CIP2A, potentiellement la première de sa classe	CI
05/10	ORIC Pharmaceuticals, Inc. : Leerink Partners passe de neutre à achat	ZM

Autres langues

06/10	ORIC(R) Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
05/10	ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
05/10	Oric Pharmaceuticals, Inc. and Cancer Research Uk Announce Agreement to Advance A Potential First-In-Class Cip2a-Targeted Therapy into Clinical Development
02/10	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07/09	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/09	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/09	ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
28/08	Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing
07/08	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/08	ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
03/08	ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
03/08	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/07	ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
14/07	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer
14/07	ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
14/07	Oric Pharmaceuticals Initiates Himalayas-1 Global Phase 3 Trial in Patients with Mcrpc Previously Treated with Abiraterone
02/07	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/06	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
27/05	ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
04/05	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
04/05	ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
01/05	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
17/04	ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
17/04	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings
03/04	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)